Jci_page_head_homepage_01 Jci_page_head_homepage_02
Emanuela Gussoni, Richard R. Bennett, Kristina R. Muskiewicz, Todd Meyerrose, Jan A. Nolta, Irene Gilgoff, James Stein, Yiu-mo Chan, Hart G. Lidov, Carsten G. Bönnemann, Arpad von Moers, Glenn E. Morris, Johan T. den Dunnen, Jeffrey S. Chamberlain, Louis M. Kunkel, Kenneth Weinberg
Published in Volume 110, Issue 6
J Clin Invest. 2002; 110(6):807–814 doi:10.1172/JCI16098
Abstract | Full text | PDF
Options: View larger image (or click on image)
Jci0216098
Figure 5

Analysis of dystrophin transcripts expressed in DMD-BMT1’s muscle. (a) U43–47 is unaffected control cDNA amplified with primers C43F-C47R; D43–47 and D43–48 are DMD-BMT1’s cDNA amplified using primers C43F-C47R or C43F-C48R, respectively. D43-48 shows the presence of three transcripts: del45 (655 bp), 43-46 (507 bp), and 44-48 (357 bp). (b) Schematic diagram of dystrophin transcripts amplified by RT-PCR and sequenced in DMD-BMT1. WT, wild type. (c) Amplification of full-length, donor-derived dystrophin in DMD-BMT1 (D43–45, D45–46) and in an unaffected control (U43–45, U45–46). (d) Quantitative RT-PCR analysis on total cDNA derived from DMD-BMT1 skeletal muscle. The cDNA was amplified using primers specific for the 45del isoform (dark blue), 44-48 in-frame truncated dystrophin (light blue), 43-46 in-frame truncated dystrophin (pink), and wild-type dystrophin (green). ΔRn, Δ reaction.